Literature DB >> 8364582

An alternatively-spliced mRNA in the carboxy terminus of the neurofibromatosis type 1 (NF1) gene is expressed in muscle.

D H Gutman1, L B Andersen, J L Cole, M Swaroop, F S Collins.   

Abstract

The gene for neurofibromatosis type 1 (NF1) was identified by positional cloning and found to contain two alternatively spliced exons. The first described alternatively spliced exon (exon 23a) is located within the GAP-related domain of the gene and inserts an additional 63 nucleotides into the NF1 mRNA. The second alternatively spliced exon (exon 48a) is located near the extreme carboxy terminus of the gene and inserts an additional 54 nucleotides into the mRNA. This second isoform, termed 3'ALT, was originally detected while screening a fetal brain cDNA library. Examination of its expression by reverse-transcribed RNA PCR demonstrates high level of expression in cardiac muscle, skeletal muscle and smooth muscle. Trace levels of expression are detected in brain and nerve. The 3'ALT isoform is expressed in fetal cardiac muscle, adult left ventricle and cardiac Purkinje cells. Further confirmation of the existence of this isoform was obtained by blotting the PCR products with a radiolabeled oligonucleotide entirely derived from sequences contained within exon 48a and by direct sequencing of the PCR products. Additionally, this isoform is expressed in muscle tissues from other vertebrate species. The expression of this isoform in muscle suggests that the NF1 gene may play additional tissue-specific roles in muscle development and signal transduction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8364582     DOI: 10.1093/hmg/2.7.989

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  15 in total

1.  A potential role for NF1 mRNA editing in the pathogenesis of NF1 tumors.

Authors:  A J Cappione; B L French; G R Skuse
Journal:  Am J Hum Genet       Date:  1997-02       Impact factor: 11.025

2.  Cold shock induces the insertion of a cryptic exon in the neurofibromatosis type 1 (NF1) mRNA.

Authors:  E Ars; E Serra; S de la Luna; X Estivill; C Lázaro
Journal:  Nucleic Acids Res       Date:  2000-03-15       Impact factor: 16.971

Review 3.  Alternative splicing of the neurofibromatosis type I pre-mRNA.

Authors:  Victoria A Barron; Hua Lou
Journal:  Biosci Rep       Date:  2012-04-01       Impact factor: 3.840

4.  NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer.

Authors:  T Cacev; S Radosević; R Spaventi; K Pavelić; S Kapitanović
Journal:  Gut       Date:  2005-04-19       Impact factor: 23.059

5.  Neurofibromatosis type 1 alternative splicing is a key regulator of Ras signaling in neurons.

Authors:  Melissa N Hinman; Alok Sharma; Guangbin Luo; Hua Lou
Journal:  Mol Cell Biol       Date:  2014-04-07       Impact factor: 4.272

Review 6.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

Review 7.  Molecular genetics of neurofibromatosis type 1 (NF1).

Authors:  M H Shen; P S Harper; M Upadhyaya
Journal:  J Med Genet       Date:  1996-01       Impact factor: 6.318

8.  Analysis of an alternatively spliced exon of the neurofibromatosis type 1 gene in cultured melanocytes from patients with neurofibromatosis 1.

Authors:  I Eisenbarth; S Hoffmeyer; D Kaufmann; G Assum; W Krone
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

9.  A novel RsaI polymorphism within intron 39 of the neurofibromatosis type 1 (NF1) gene.

Authors:  D Rodenhiser; K Hovland
Journal:  Hum Genet       Date:  1995-02       Impact factor: 4.132

10.  Alternative splicing in the differentiation of human embryonic stem cells into cardiac precursors.

Authors:  Nathan Salomonis; Brandon Nelson; Karen Vranizan; Alexander R Pico; Kristina Hanspers; Allan Kuchinsky; Linda Ta; Mark Mercola; Bruce R Conklin
Journal:  PLoS Comput Biol       Date:  2009-11-06       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.